HPC/Exascale Centre of Excellence in Personalised Medicine - PerMedCoE

Acronym

PerMedCoE

Description of the granted funding

Personalised Medicine (PerMed) opens unexplored frontiers to treat diseases at the individual level combining clinical and omics information. However, the performances of the current simulation software are still insufficient to tackle medical problems such as tumour evolution or patient-specific treatments. The challenge is to develop a sustainable roadmap to scale-up the essential software for the cell-level simulation to the new European HPC/Exascale systems. Simulation of cellular mechanistic models are essential for the translation of omic data to medical relevant actions and these should be accessible to the end-users in the appropriate environment of the PerMed-specific big confidential data. The goal of the HPC/Exascale Centre of Excellence in Personalised Medicine (PerMedCoE) is to provide an efficient and sustainable entry point to the HPC/Exascale-upgraded methodology to translate omics analyses into actionable models of cellular functions of medical relevance. It will accomplish so by 1) optimising four core applications for cell-level simulations to the new pre-exascale platforms; 2) integrating PerMed into the new European HPC/Exascale ecosystem, by offering access to HPC/Exascale-adapted and optimised software; 3) running a comprehensive set of PerMed use cases; & 4) building the basis for the sustainability of the PerMedCoE by coordinating PerMed and HPC communities, and reaching out to industrial and academic end-users, with use cases, training, expertise, and best practices. The PerMedCoE cell-level simulations will fill the gap between the molecular- and organ-level simulations from the CompBioMed and BioExcel CoEs with which this proposal is aligned at different levels. It will connect methods’ developers with HPC, HTC and HPDA experts (at POP and HiDALGO CoEs). Finally, the PerMedCoE will work with biomedical consortia (i.e. ELIXIR, LifeTime initiative) and pre-exascale infrastructures (BSC and CSC), including a substantial co-design effort.
Show more

Starting year

2020

End year

2023

Granted funding

509 900 €
Participant
ELEM BIOTECH SL (ES)
104 375 €
Participant
UNIVERSITAETSKLINIKUM HEIDELBERG (DE)
473 500 €
Participant
ATOS IT SOLUTIONS AND SERVICES IBERIA SL (ES)
32 000 €
Third party
FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES)
42 500 €
Third party
FUNDACIO CENTRE DE REGULACIO GENOMICA (ES)
122 500 €
Participant
BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION (ES)
1 146 273.84 €
Coordinator
UNIVERSITE DU LUXEMBOURG (LU)
739 840 €
Participant
INSTITUT CURIE (FR)
508 750 €
Participant
IBM RESEARCH GMBH (CH)
531 250 €
Participant
UNIVERZA V LJUBLJANI (SI)
103 250 €
Participant
EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE)
378 974.25 €
Participant
MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC) (DE)
149 425 €
Participant
KUNGLIGA TEKNISKA HOEGSKOLAN (SE)
299 875 €
Participant
ATOS SPAIN SA (ES)
388 404.41 €
Participant

Amount granted

4 999 568 €

Funder

European Union

Funding instrument

Research and Innovation action

Framework programme

Horizon 2020 Framework Programme

Call

Programme part
EXCELLENT SCIENCE - Research Infrastructures (5226)
Development, deployment and operation of ICT-based e-infrastructures (5230)
Topic
Centres of Excellence in exascale computing (INFRAEDI-05-2020)
Call ID
H2020-INFRAEDI-2019-1

Other information

Funding decision number

951773

Identified topics

cancer